Начало・Списък с акции・Sana Biotechnology Inc

Sana Biotechnology Inc

Затворен

СекторЗдравеопазване

3.56 -3.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.38

Максимум

3.65

Ключови измерители
By Trading Economics
Приходи	-16M -64M
EPS	-0.13
Служители	142
EBITDA	-21M -65M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+117.98% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	120M 1B
Предишно отваряне	6.82
Предишно затваряне	3.56

Настроения в новините

By Acuity

25%

75%

87 / 340 Класиране в Healthcare

Sana Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 20:06 ч. UTC

News

Sana Biotechnology shares declined amid mixed analyst ratings and broader market challenges, with BofA lowering its price target to $6.00 from $7.00.

13.08.2026 г., 19:36 ч. UTC

Sana Biotechnology Inc shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

12.08.2026 г., 23:46 ч. UTC

Sana Biotechnology Inc shares are lower in after-market hours, with no specific news identified to explain the price movement.

11.08.2026 г., 19:31 ч. UTC

News

Sana Biotechnology shares are higher following Q2 results showing an adjusted EPS of -$0.13, exceeding estimates, and a $25 million investment from Mayo Clinic.

10.08.2026 г., 23:01 ч. UTC

News

Sana Biotechnology Inc shares are lower in after-market hours following a second-quarter loss of $63.6 million, despite an adjusted EPS that exceeded expectations.

7.08.2026 г., 19:56 ч. UTC

Sana Biotechnology Inc. shares are higher, supported by broader market dynamics following a disappointing jobs report easing interest rate concerns.

5.08.2026 г., 19:56 ч. UTC

Sana Biotechnology Inc. is trading higher during Wednesday's session, having peaked earlier before pulling back slightly while remaining above its 20-day moving average.

4.08.2026 г., 20:05 ч. UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

3.08.2026 г., 19:46 ч. UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

31.07.2026 г., 23:06 ч. UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

30.07.2026 г., 19:29 ч. UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

29.07.2026 г., 23:36 ч. UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

28.07.2026 г., 18:03 ч. UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

27.07.2026 г., 19:07 ч. UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

24.07.2026 г., 18:26 ч. UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

22.07.2026 г., 19:36 ч. UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

20.07.2026 г., 17:56 ч. UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Сравнение с други в отрасъла

Ценова промяна

Sana Biotechnology Inc Прогноза

Ценова цел

By TipRanks

117.98% нагоре

12-месечна прогноза

Среден 8 USD 117.98%

Висок 12 USD

Нисък 6 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Sana Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Sana Biotechnology Inc през последните 3 месеца.

Настроение

By Acuity

87 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.